Previous close | 22.61 |
Open | 22.57 |
Bid | 23.13 x 200 |
Ask | 23.19 x 200 |
Day's range | 22.57 - 23.20 |
52-week range | 22.07 - 59.61 |
Volume | |
Avg. volume | 720,355 |
Market cap | 1.121B |
Beta (5Y monthly) | 1.37 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.66 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 53.13 |
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
MASON, Ohio, April 18, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with
MASON, Ohio, April 10, 2024--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2024 financial results on Wednesday, May 1, 2024.